Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL Believe
2023-509143-27-00Phase 2Authorised
- Sponsor
- Ascendis Pharma
- Start
- Dec 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of TransCon IL-2 β⁄γ in Non-hematologic malignancy, ovarian cancer, melanoma and 4 more (8 arms), sponsored by Ascendis Pharma. Primary endpoint: Incidence and severity of serious adverse events and adverse events. Planned start Dec 2023; status: authorised.
02
Drugs
TransCon IL-2 β⁄γ
03
Conditions
Non-hematologic malignancyovarian cancermelanomaCervical Cancer (CC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509143-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509143-27-00.